Fenwick Represents Melinta Therapeutics in $300M Acquisition by CorMedix

Fenwick is representing Melinta Therapeutics, a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, in its acquisition by CorMedix (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million as well as royalties on net sales of MINOCIN^® and REZZAYO™. More information can be obtained from Melinta’s announcement.

The Fenwick transaction team includes corporate partners Doug Cogen, David Michaels and Matt Rossiter and associates Rob O'Connor, Philip Ewing, Santino Labate and Sammi Chen; technology transactions partner Jake Handy and associates Kehl Sink, Phillip Yin, Taylor Muentener, Rob Ferrari, Sam Dodson and Nick Zakari and law clerk Kiyan Savar; executive compensation and employee benefits partner Marshall Mort and associates Jonathan Stephenson, Rachel Coffey and Nathan Pope; privacy and cybersecurity partner Ana Razmazma, counsel Sari Ratican and associate Natalie Kim; antitrust partners Tom Ensign and Steve Albertson, counsel Meredith Mommers and associate Susan Lee; healthcare regulatory partner Jennifer Yoo; and tax partner William Skinner and associate Kris Hatch.